Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | MEF2D | Q14814 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289471 | 1.00 | CYP4F2 (0.56) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL4404015 | 0.87 | CYP4F2 (0.58) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL4404014 | 0.87 | CYP4F2 (0.58) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL14501332 | 0.86 | CYP4F2 (0.63) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL14143301 | 0.86 | CYP4F2 (0.59) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL16050530 | 0.85 | HSP90AB1 (0.49) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL16050532 | 0.85 | HSP90AB1 (0.49) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL4683223 | 0.84 | LTB4R (0.56) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL4683225 | 0.84 | LTB4R (0.56) | CYP4F2CYP4A11SLC7A5ALDH1A1KDM4E | |
| SCHEMBL289617 | 0.84 | PPARG (0.47) | CYP4F2CYP4A11ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-11-30 | — | — | US | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| EP-3443957-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LIMINAL BIOSCIENCES LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-20200237693-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | LIMINAL BIOSCIENCES INC (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20200078324-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | Liminal Biosciences Limited (GB) | 2020-03-12 | — | — | US | disclosed |
| US-10450258-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-9114118-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2015-08-25 | — | — | US | disclosed |
| US-20150094372-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Liminal Biosciences Limited (GB) | 2015-04-02 | — | — | US | disclosed |
| US-8927765-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| WO-2014138907-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| EP-2632452-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ProMetic BioSciences Inc. (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2427416-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, CCNH, COL2A1 | CYP4F2 289/4885CYP4A11 1001/4885SLC7A5 3509/4885 |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | DCK, TOP2B, TOP2A | CYP4F2 1655/4885CYP4A11 3294/4885SLC7A5 1331/4885 |
| US-20200237693-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ADIPOR1, ADIPOR2, FN1 | CYP4F2 963/4885CYP4A11 1106/4885SLC7A5 2610/4885 |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | TYR, PAH, REN | CYP4F2 74/4885CYP4A11 26/4885SLC7A5 453/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | CYP4F2 74/4885CYP4A11 26/4885SLC7A5 453/4885 |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | COL1A1, CCNH, COL2A1 | CYP4F2 289/4885CYP4A11 1001/4885SLC7A5 3509/4885 |
| US-10450258-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | CYP4F2 161/4885CYP4A11 245/4885SLC7A5 1238/4885 |
| US-20150094372-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | TYR, PAH, REN | CYP4F2 74/4885CYP4A11 26/4885SLC7A5 453/4885 |
| US-20200078324-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, COL2A1, CCNH | CYP4F2 318/4885CYP4A11 1086/4885SLC7A5 3613/4885 |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | ADIPOR1, ADIPOR2, FN1 | CYP4F2 963/4885CYP4A11 1106/4885SLC7A5 2610/4885 |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | TYR, PAH, REN | CYP4F2 74/4885CYP4A11 26/4885SLC7A5 453/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | CYP4F2 161/4885CYP4A11 245/4885SLC7A5 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.